Navigation Links
US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment

CHARLOTTE, N.C., Nov. 9, 2010 /PRNewswire/ -- USHIFU LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 (Sonablate) and Sonatherm® 600 medical devices, is pleased to announce that 18 clinical trial sites involved in the recurrent prostate cancer trial have been initiated and opened. The recurrent prostate cancer trial, or STAR trial, is a multi-center clinical study of HIFU with the Sonablate device (Sonablate HIFU) for the treatment of locally recurrent prostate cancer following failed radiation therapy.

(Logo:  )

(Logo:  )

"It is gratifying to have nearly completed the opening of all 20 trial sites, particularly with some of the most prestigious institutions in North America," said US HIFU's CEO Steve Puckett, Jr. "I believe I represent the sentiment of all of our sites that we are moving as quickly as possible toward trial completion in eager anticipation of bringing HIFU to prostate cancer patients in this country. This has been our top priority since founding the company in 2004."

The following list represents the majority of the current clinical trial sites. In addition, two well-known and–respected facilities are located in Southeast Texas and Southern Wisconsin; visit (search term fsi003) for the most recent and comprehensive listing:SITE


Toronto, Ontario, CanadaChesapeake Urology Research Associates

Towson, Md.David Geffen School of Medicine UCLA

Los Angeles, Calif.Fox Chase Cancer Center

Philadelphia, Pa. Indiana University Medical Center

Indianapolis, Ind.Iowa Clinic

Des Moines, IowaLondon Health Sciences Centre, UWO

London, Ontario, CanadaManitoba Prostate Centre

Winnipeg, Manitoba, CanadaMetropolitan Urology

Jeffersonville, Ind.New York University School of Medicine

New York, N.Y.Specialists in Urology

Naples, Fla.Tulane University School of Medicine

New Orleans, La.University Hospitals Case Medical Center

Cleveland, OhioUniversity of Illinois

Chicago, Ill.Urologic Consultants of Southeastern Pennsylvania

Bala Cynwyd, Pa. VA Connecticut Healthcare System/Yale University

West Haven, Conn.Walter Reed Army Medical Center

Washington, D.C. A partial list of criteria for inclusion in the recurrent trial, which is now in the pivotal phase, includes:

  • Men with biopsy-confirmed, organ-confined recurrent prostate cancer
  • Ages 40-85
  • Treated with external beam radiation therapy (EBRT) two or more years prior

  • For more information on the STAR trial, including a full list of inclusion criteria, please call (877) 874-4389 or visit (click on clinical information) or (search term fsi003).  

    About USHIFU LLCUSHIFU LLC (US HIFU), a privately held healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. US HIFU manufactures the Sonablate® 500 medical device and is focused currently on treating primary and recurrent prostate cancer using Sonablate® HIFU. The company is engaged in ongoing research for technological advancements for the Sonablate® system or other ultrasound applications. US HIFU was founded in 2004 and is headquartered in Charlotte, N.C. Additional information can be found at

    About the Sonablate® 500The Sonablate® 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by Focus Surgery, Inc. Takai Hospital Supply Ltd. distributes the Sonablate® 500 in Southeast Asia. The Sonablate® 500 is not approved for use in the U.S. The Sonablate® 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate® 500 for the treatment of prostate cancer. HIFU for prostate cancer with the Sonablate® 500 is approved or authorized and commercially available in more than 30 countries outside the U.S.  


    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
    2. Arcadia Resources Announces Improved Fiscal 2011 Second Quarter Results
    3. Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting
    4. NxStage Announces Fourth Quarter 2010 Investor Conference Schedule
    5. Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
    6. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
    7. Hologic Announces Fourth Quarter and Fiscal 2010 Operating Results
    8. Accuray Announces Results for First Quarter of Fiscal 2011
    9. Mindray Announces Third Quarter 2010 Financial Results
    10. Mindray Medical Announces Participation in Upcoming Investor Conferences
    11. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
    Post Your Comments:
    (Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
    (Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
    (Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
    (Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s ... America Annual Meeting from November 29 to December 4, 2015. , MED-TAB ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
    (Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
    Breaking Medicine News(10 mins):